NewsBenzingaJP Morgan mantiene il giudizio “Overweight” su Cellebrite DI, abbassa il prezzo obiettivo a 15 dollari JP Morgan mantiene il giudizio “Overweight” su Cellebrite DI, abbassa il prezzo obiettivo a 15 dollari Benzinga 2026.11.13 20:09 (GMT+0) Open on Benzinga Other news Meta Internally Tests Prediction Market App 'Takes' Leerink Partners Maintains Outperform on Twist Bioscience, Lowers Price Target to $175 Microsoft Says Infrastructure Stabilizes As Queued Messages Drain And Traffic Rebalances, With No ETA For Full Recovery JP Morgan Maintains Overweight on Sea, Lowers Price Target to $132 JP Morgan Maintains Overweight on Lithium Americas, Lowers Price Target to $5 JP Morgan Maintains Overweight on Cellebrite DI, Lowers Price Target to $15
Microsoft Says Infrastructure Stabilizes As Queued Messages Drain And Traffic Rebalances, With No ETA For Full Recovery
